What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia.
about
What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
What are we paying for? A cost ...... teoporotic women in Australia.
@en
What are we paying for? A cost ...... teoporotic women in Australia.
@nl
type
label
What are we paying for? A cost ...... teoporotic women in Australia.
@en
What are we paying for? A cost ...... teoporotic women in Australia.
@nl
prefLabel
What are we paying for? A cost ...... teoporotic women in Australia.
@en
What are we paying for? A cost ...... teoporotic women in Australia.
@nl
P2093
P2860
P921
P1476
What are we paying for? A cost ...... teoporotic women in Australia.
@en
P2093
Ainul Shakirah Shafie
Nneka Orji
Sofoora Kawsar Usman
P2860
P2888
P356
10.1186/S12962-016-0060-5
P577
2016-10-13T00:00:00Z
P6179
1000795245